Eledon Pharmaceuticals reported key developments in its immunosuppression research, including successful use of tegoprubart in a genetically modified pig kidney transplant and initial positive data from type 1 diabetes islet transplantation. The company raised $85 million in an oversubscribed offering, extending its cash runway to the end of 2026. The Phase 2 BESTOW trial results for kidney transplantation are expected in Q4 2025.